191 related articles for article (PubMed ID: 27233154)
21. Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha?
Cigolini M; Tonoli M; Borgato L; Frigotto L; Manzato F; Zeminian S; Cardinale C; Camin M; Chiaramonte E; De Sandre G; Lunardi C
Atherosclerosis; 1999 Mar; 143(1):81-90. PubMed ID: 10208482
[TBL] [Abstract][Full Text] [Related]
22. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity.
Shimomura I; Funahashi T; Takahashi M; Maeda K; Kotani K; Nakamura T; Yamashita S; Miura M; Fukuda Y; Takemura K; Tokunaga K; Matsuzawa Y
Nat Med; 1996 Jul; 2(7):800-3. PubMed ID: 8673927
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke.
Chen R; Yan J; Liu P; Wang Z; Wang C
Metab Brain Dis; 2017 Jun; 32(3):667-673. PubMed ID: 28378106
[TBL] [Abstract][Full Text] [Related]
24. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance.
Bastard JP; Piéroni L; Hainque B
Diabetes Metab Res Rev; 2000; 16(3):192-201. PubMed ID: 10867719
[TBL] [Abstract][Full Text] [Related]
25. Adipose Tissue-Derived Plasminogen Activator Inhibitor-1 Function and Regulation.
Kaji H
Compr Physiol; 2016 Sep; 6(4):1873-1896. PubMed ID: 27783862
[TBL] [Abstract][Full Text] [Related]
26. Human visceral adipose tissue and the plasminogen activator inhibitor type 1.
Lindeman JH; Pijl H; Toet K; Eilers PH; van Ramshorst B; Buijs MM; van Bockel JH; Kooistra T
Int J Obes (Lond); 2007 Nov; 31(11):1671-9. PubMed ID: 17471294
[TBL] [Abstract][Full Text] [Related]
27. Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity.
Bastard JP; Piéroni L
Biomed Pharmacother; 1999 Dec; 53(10):455-61. PubMed ID: 10665338
[TBL] [Abstract][Full Text] [Related]
28. Stimulated in vivo synthesis of plasminogen activator inhibitor-1 in human adipose tissue.
Ekström M; Liska J; Eriksson P; Sverremark-Ekström E; Tornvall P
Thromb Haemost; 2012 Sep; 108(3):485-92. PubMed ID: 22740034
[TBL] [Abstract][Full Text] [Related]
29. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity.
Malavazos AE; Ermetici F; Cereda E; Coman C; Locati M; Morricone L; Corsi MM; Ambrosi B
Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):523-30. PubMed ID: 18083357
[TBL] [Abstract][Full Text] [Related]
30. Degree of obesity influences the relationship of PAI-1 with body fat distribution and metabolic variables in African women.
Barnard SA; Pieters M; Nienaber-Rousseau C; Kruger HS
Thromb Res; 2016 Oct; 146():95-102. PubMed ID: 27639099
[TBL] [Abstract][Full Text] [Related]
31. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors.
You T; Yang R; Lyles MF; Gong D; Nicklas BJ
Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E741-7. PubMed ID: 15562250
[TBL] [Abstract][Full Text] [Related]
32. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women.
Mertens I; Van der Planken M; Corthouts B; Wauters M; Peiffer F; De Leeuw I; Van Gaal L
Horm Metab Res; 2001 Oct; 33(10):602-7. PubMed ID: 11607880
[TBL] [Abstract][Full Text] [Related]
33. PAI-1 and TNF-α profiles of adipose tissue in obese cardiovascular disease patients.
Bilgic Gazioglu S; Akan G; Atalar F; Erten G
Int J Clin Exp Pathol; 2015; 8(12):15919-25. PubMed ID: 26884864
[TBL] [Abstract][Full Text] [Related]
34. Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor Type I by proinsulin.
Nordt TK; Bode C; Sobel BE
Diabetologia; 2001 Sep; 44(9):1121-4. PubMed ID: 11596666
[TBL] [Abstract][Full Text] [Related]
35. Plasminogen activator inhibitor-1 and haemostasis in obesity.
Mutch NJ; Wilson HM; Booth NA
Proc Nutr Soc; 2001 Aug; 60(3):341-7. PubMed ID: 11681808
[TBL] [Abstract][Full Text] [Related]
36. Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration.
Giltay EJ; Elbers JM; Gooren LJ; Emeis JJ; Kooistra T; Asscheman H; Stehouwer CD
Arterioscler Thromb Vasc Biol; 1998 Nov; 18(11):1716-22. PubMed ID: 9812909
[TBL] [Abstract][Full Text] [Related]
37. Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo.
Yudkin JS; Coppack SW; Bulmer K; Rawesh A; Mohamed-Ali V
Thromb Res; 1999 Oct; 96(1):1-9. PubMed ID: 10554079
[TBL] [Abstract][Full Text] [Related]
38. Relationships between fibrinolytic and inflammatory parameters in human adipose tissue: strong contribution of TNFalpha receptors to PAI-1 levels.
Bastelica D; Mavri A; Verdierl M; Berthet B; Juhan-Vague I; Alessi MC
Thromb Haemost; 2002 Sep; 88(3):481-7. PubMed ID: 12353079
[TBL] [Abstract][Full Text] [Related]
39. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women.
Janand-Delenne B; Chagnaud C; Raccah D; Alessi MC; Juhan-Vague I; Vague P
Int J Obes Relat Metab Disord; 1998 Apr; 22(4):312-7. PubMed ID: 9578235
[TBL] [Abstract][Full Text] [Related]
40. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity.
Juhan-Vague I; Alessi MC; Morange PE
Ann Med; 2000 Dec; 32 Suppl 1():78-84. PubMed ID: 11209987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
